Identify Sotyktu’s Niche in Psoriasis Treatment
March 2023
Sotyktu (deucravacitinib) will be a new oral option for adults with moderate to severe plaque psoriasis.
It’s the first in a new med class that blocks tyrosine kinase 2 (TYK2)...a protein linked to inflammation in psoriasis.
Once-daily Sotyktu appears more effective than twice-daily oral Otezla (apremilast), a phosphodiesterase 4 inhibitor.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive